Core Points - The company has issued a special report on the use of raised funds as of June 30, 2025, ensuring the information is true, accurate, and complete [1] - The company raised a total of RMB 276 million through the issuance of convertible bonds in March 2022 and RMB 301.99 million through a private placement of A-shares in September 2023 [2][5] - The company has established a fund management system to ensure the effective use of raised funds and protect investor rights [2][3] Fundraising Overview - The total amount raised from the convertible bonds was RMB 276 million, with a net amount of RMB 272 million after deducting issuance costs [1] - The total amount raised from the A-share issuance was RMB 301.99 million, with a net amount of RMB 294.84 million after deducting issuance costs [2] - As of June 30, 2025, the company has used a total of RMB 421.71 million of the raised funds, with RMB 155.79 million remaining [5][6] Fund Management and Usage - The company has implemented a dedicated account management system for the raised funds, ensuring compliance with relevant laws and regulations [2][3] - As of June 30, 2025, several fundraising accounts have been closed, and the remaining funds are stored in dedicated accounts [3][4] - The company has not engaged in any temporary use of idle funds for working capital or cash management [5][6] Project Updates and Changes - The "Construction Project of Centralized Preparation Center for Medical Institutions in Shaanxi Province" has been delayed and the completion date has been extended to December 31, 2024, due to various factors [6][9] - The company has decided to terminate the project and use the remaining funds for permanent working capital, following board and supervisory approvals [6][9] - The company has also terminated the "Quality Inspection and Testing Shared Platform Upgrade Project" and redirected the remaining funds to working capital [6][9] Compliance and Disclosure - The company has ensured that all fundraising activities and fund usage have been disclosed in a timely, truthful, accurate, and complete manner [5][6] - There have been no violations in the management of raised funds during the reporting period [5][6]

（2025 年 月） 陕西盘龙药业集团股份有限公司募集资金管理制度 陕西盘龙药业集团股份有限公司 第一章 总则 第一条 为规范陕西盘龙药业集团股份有限公司（以下简称"公司"）募集 资金管理，提高募集资金使用效率，根据《中华人民共和国公司法》、 《中华人民 共和国证券法》 （以下简称"证券法"）、 《首次公开发行股票注册管理办法》、 《深 《深圳证券交易所上市公司监管指引 1 号—主板上 圳证券交易所股票上市规则》、 市公司规范运作》《上市公司募集资金监管规则》、《陕西盘龙药业集团股份有限 公司章程》 （以下简称"公司章程"）以及其他有关法律、法规的规定，并结合公 司实际情况，制定本制度。 第二条 本管理制度所称募集资金是指公司通过向不特定对象发行证券（包 括首次公开发行股票、配股、增发、发行可转换公司债券、发行分离交易的可转 换公司债券、发行权证等）以及向特定对象发行股票向投资者募集并用于特定用 途的资金。 发行股票、可转换债券或其他证券的募集资金到位后，公司应及时办理验资 手续，由具有证券从业资格的会计师事务所出具验资报告。 第三条 公司董事会应当对募集资金投资项目的可行性进行充分论证，确信 投资项目具有较 ...

Core Viewpoint - The company has completed certain fundraising projects and plans to permanently supplement its working capital with the remaining funds, which is deemed a prudent decision based on the actual progress of the projects and operational needs [1][6][8]. Fundraising Overview - The company raised a total of RMB 719,999,998.10 by issuing 41,618,497 shares at a price of RMB 17.3 per share, with a net amount of RMB 705,505,113.82 after deducting issuance costs [1][2]. - The funds are managed in a dedicated account with tripartite and quadripartite supervision agreements in place [2]. Fund Usage and Status - The raised funds were allocated to several projects, including the "High-end Special Material Equipment Intelligent Manufacturing Project," "Engineering Technology R&D Center," and "Ship and Marine Engineering Equipment Manufacturing Quality Improvement Project," as well as for working capital and debt repayment [2][3]. - As of June 30, 2025, the balance in the fundraising account was RMB 499,891,926.54 [3]. Project Completion and Surplus Funds - The "Engineering Technology R&D Center" project has reached its intended use status, allowing for its completion [4]. - The surplus funds from this project will be transferred to the company's general bank account for permanent working capital supplementation [5]. Reasons for Surplus Funds - The surplus is attributed to strict adherence to fundraising management regulations, cost-effective procurement practices, and the substitution of imported equipment with domestic alternatives, which significantly reduced costs [4][5]. Impact of Fund Reallocation - The decision to reallocate surplus funds is expected to enhance the efficiency of fund usage and align with the company's operational needs, without harming the interests of the company or its shareholders [6][8]. Review Procedures - The independent directors, board of directors, and supervisory board have all approved the decision to reallocate surplus funds, confirming compliance with relevant regulations and the absence of any detrimental effects on shareholder interests [6][8][9].

Core Points - The board of directors of Rongxin Education and Cultural Industry Development Co., Ltd. held its eighth meeting of the fourth session on August 26, 2025, to discuss various proposals [1][2][3]. Group 1: Meeting Details - The meeting was convened by Chairwoman Wang Yihua and attended by all 8 directors, with senior management present [1]. - The meeting complied with relevant laws, regulations, and the company's articles of association [1]. Group 2: Resolutions Passed - The board approved the proposal regarding the 2025 semi-annual report and summary, confirming the accuracy and completeness of financial information [2]. - The board also approved a special report on the management and use of raised funds for the first half of 2025, confirming compliance with regulations [2]. - A proposal to amend the company's articles of association was approved, with authorization for management to handle subsequent registration matters [3]. - The board approved the proposal to revise corporate governance-related systems, which will also require shareholder approval [5]. - A proposal to use part of the excess raised funds to permanently supplement working capital was approved, pending shareholder approval [6]. - The board scheduled the second extraordinary general meeting of shareholders for September 15, 2025 [6]. Group 3: Voting Results - All proposals received unanimous support with 8 votes in favor, and no votes against or abstentions [2][3][5][6]. Group 4: Reference Documents - The company disclosed relevant documents on the Giant Tide Information Network, including the meeting resolutions and audit committee decisions [6].

证券代码：301428 证券简称：世纪恒通 公告编号：2025-051 世纪恒通科技股份有限公司 第四届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、会议召开情况 世纪恒通科技股份有限公司（以下简称"公司"）第四届董事会第十六次会议 于2025年8月26日在公司会议室以现场结合线上通讯表决方式召开，会议通知已 于2025年8月15日以电子邮件方式送达全体董事。本次会议应出席董事7人，实际 出席董事7人（其中，董事杨兴荣先生、陶正林先生及独立董事钟广宏先生以通 讯方式出席会议）。会议由董事长杨兴海先生召集并主持，公司监事、高级管理 人员列席本次会议。本次会议的召集、召开程序及表决方式符合《中华人民共和 国公司法》等法律、法规、规范性文件和《公司章程》的有关规定，会议合法、 有效。 二、会议审议情况 经与会董事认真审议，充分讨论，审慎表决，会议审议通过了以下议案： 董事会认真审阅了公司《2025 年半年度报告》及其摘要，认为公司《2025 年半年度报告》及其摘要的编制和审议程序符合法律、行政法规和中国证监会的 规定，报告内容真实 ...

Fundraising Overview - The total amount raised from the initial public offering (IPO) in 2021 was RMB 62,532 million, with a net amount of RMB 55,925.88 million after deducting issuance costs of RMB 6,606.12 million [1][3] - As of June 30, 2025, the total amount of funds raised from the IPO was RMB 58,997.34 million, with various deductions leading to an actual investment amount of RMB 55,925.88 million [2][3] Fund Utilization - By June 30, 2025, the actual investment amount from the 2021 IPO was RMB 45,692.77 million, with specific allocations detailed in the report [8][9] - The company approved the use of surplus funds from the "Fermentation Method L-Alanine 5000 tons/year technical transformation and expansion project" and "Alternate annual production of 25,000 tons of L-Alanine and L-Valine project" to permanently supplement working capital [3][9] 2022 Fundraising - In 2022, the company raised RMB 699,999,981.40 through a targeted issuance of A-shares, with a net amount of RMB 68,380.91 million after deducting issuance costs of RMB 1,619.09 million [4][5] - As of June 30, 2025, the total investment from the 2022 fundraising was RMB 68,404.964 million, with specific allocations also detailed in the report [8][12] Fund Management - The company has established a fundraising management method to ensure the proper storage, approval, use, and supervision of the raised funds, adhering to relevant laws and regulations [5][9] - The company has signed tripartite and quadripartite supervision agreements with banks and securities firms to ensure compliance in the management of the raised funds [7][8] Project Updates - The company has not made any changes to the fundraising projects from both the 2021 IPO and the 2022 targeted issuance [10][11] - The company has approved the addition of products such as L-Valine and Inositol to the annual production of 50,000 tons of bio-based succinic acid and bio-based product raw material production base construction project [9][12]

Fundraising Overview - The company raised a total of RMB 284,614,308.00, with a net amount of RMB 280,612,310.30 after deducting issuance costs [1][2] - As of June 30, 2025, the balance of the special account for raised funds was RMB 231,078,223.02 [1][2] Fund Management - The company has implemented strict management and usage protocols for the raised funds, adhering to relevant regulations and internal guidelines [1][4] - A tripartite supervision agreement was signed with the sponsor and the bank managing the special account [1][3] Fund Usage - A total of RMB 49,576,527.16 was invested in fundraising projects during the reporting period, with no changes in the purpose of the raised funds [2][4] - The company has not experienced any significant changes in the feasibility of the fundraising projects [2][4] Cash Management - The company has not used any temporarily idle raised funds for cash management during the reporting period [3][4] - A resolution was passed to allow the use of temporarily idle funds for cash management, but as of June 30, 2025, the balance for such management was RMB 0.00 [3][4] Loan to Subsidiary - The company approved a loan of up to RMB 26,000,000.00 to its subsidiary, Jiangsu Tianyan Medical Technology Co., Ltd., for project implementation [3][4] Compliance and Disclosure - The company has complied with all relevant laws and regulations regarding the use of raised funds and has disclosed the usage status in a timely manner [4]

Core Viewpoint - The report outlines the fundraising and usage status of Xiamen Jiarong Technology Co., Ltd. as of June 30, 2025, highlighting compliance with regulatory requirements and detailing the management of raised funds [1][3]. Fundraising Overview - The company raised a total of RMB 1,118.30 million through the issuance of 29.13 million shares at a price of RMB 38.39 per share, with a net amount of RMB 989.01 million after deducting issuance costs of RMB 129.29 million [1][2]. - The funds were deposited into a designated bank account on April 18, 2022, and verified by an accounting firm [1]. Fund Usage and Balance - As of June 30, 2025, the company directly invested RMB 1.66 million in fundraising projects during the reporting period, with a total of RMB 48.70 million invested cumulatively [5][8]. - The company has a cash management balance of RMB 53.10 million from idle funds, which is being used for high-security, liquid financial products [5][9]. Fund Management Practices - The company has established a fundraising management method to ensure the proper storage, approval, usage, and supervision of the raised funds, adhering to principles of regulation, safety, efficiency, and transparency [2][3]. - The company signed tripartite supervision agreements with several banks to clarify the rights and obligations of all parties involved in the management of the raised funds [3][4]. Project Implementation and Adjustments - The company has made adjustments to the implementation timelines of several projects, extending deadlines to December 31, 2025, due to external macroeconomic factors and operational challenges [8][9]. - The company plans to enhance its project implementation locations and structures to better support its long-term development strategy [8][9]. Compliance and Reporting - The company has complied with the relevant regulations and has disclosed the usage of raised funds in a timely manner, with no violations reported regarding the management of these funds [8][9].

Fundraising Overview - The company raised a total of RMB 2,776,683,957.38 from its initial public offering, with all funds received by March 30, 2022 [1] - As of June 30, 2025, the total amount of funds used from the IPO was RMB 2,787,050,000.00, with a remaining balance of RMB 416,321,811.25 [1][2] Fund Utilization - The funds were allocated as follows: RMB 883,144,104.24 directly to project expenditures, RMB 1,102,864,694.13 for replacing pre-invested project funds, and RMB 450,000,000.00 for supplementing working capital [1] - The company has not used idle funds to temporarily supplement working capital during the reporting period [2] Fund Management - The company established a dedicated fund management system to ensure proper use and disclosure of the raised funds, adhering to regulatory guidelines [1] - Funds are stored in three dedicated accounts with specific banks, ensuring strict approval processes for fund usage [1] Investment Projects - The company has not experienced any abnormal situations regarding its investment projects, and all projects are progressing as planned [2] - The company utilized RMB 93,204.40 million of excess funds for a new project aimed at producing 30,000 tons of high-performance carbon fiber, with all funds fully contributed by June 30, 2024 [2][3] Cash Management - The company approved a plan to manage idle funds, allowing for investment in low-risk financial products with a maximum limit of RMB 67,413.77 million [2] - As of June 30, 2025, the company redeemed all cash management products, totaling RMB 12,280 million [3] Compliance and Reporting - The company has complied with all regulations regarding the use and disclosure of raised funds, with no violations reported [2] - There have been no changes in the use of fundraising projects during the reporting period [2]

General Principles - The purpose of the fundraising management measures is to standardize the use and management of funds raised by Jilin Expressway Co., Ltd. in accordance with relevant laws and regulations [1][20] - The funds raised refer to the capital obtained through public and non-public issuance of securities, excluding funds raised for equity incentive plans [1] Fund Storage - The company must store the raised funds in a special account approved by the board of directors, and these funds cannot be used for other purposes [3][4] - A tripartite supervision agreement must be signed with the sponsor or independent financial advisor and the commercial bank within one month of the funds being received [3][4] Fund Usage - The company must use the raised funds strictly according to the purposes listed in the prospectus and cannot change the usage without proper procedures [2][5] - The board of directors should continuously monitor the storage, management, and usage of the raised funds to prevent investment risks [5][6] - Funds should primarily be used for the main business and not for financial investments or providing funds to controlling shareholders or related parties [6][7] Changes in Fund Usage - Any changes in the use of raised funds must be approved by the board of directors and disclosed to shareholders [21][22] - If a project funded by raised capital is not completed on time, the company must report the reasons and the current status of the funds [11][12] Management and Supervision - The financial department must maintain a detailed record of the usage of raised funds, and internal audits should be conducted at least biannually [26][27] - The sponsor or independent financial advisor is responsible for ongoing supervision of the management and usage of the raised funds [28][29]